Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
CURRENC Group | CURR | Nov 4, 2024 | 1.98 | 0.00 |
Curtiss-Wright | CW | Nov 4, 2024 | 350.01 | +0.34 |
Cushing Mlp & Infrastructure Total Return Fund | SRV | Nov 4, 2024 | 40.07 | -1.55 |
Cushman & Wakefield | CWK | Nov 4, 2024 | 13.14 | +0.84 |
Custom Truck One Source | CTOS | Nov 4, 2024 | 4.11 | +1.99 |
Customers Bancorp | CUBI | Nov 4, 2024 | 45.66 | -0.04 |
Customers Bancorp E Pref | CUBI-E | Nov 4, 2024 | 25.75 | -0.19 |
Customers Bancorp F Pref | CUBI-F | Nov 4, 2024 | 25.25 | -0.20 |
Cutera | CUTR | Nov 4, 2024 | 0.56 | -4.86 |
CVB Financial | CVBF | Nov 4, 2024 | 18.96 | -1.61 |
CVD Equipment | CVV | Nov 4, 2024 | 2.91 | -1.36 |
CVR Energy | CVI | Nov 4, 2024 | 16.44 | +2.94 |
Cvr Partners LP Unit | UAN | Nov 4, 2024 | 66.71 | +1.21 |
CVRx | CVRX | Nov 4, 2024 | 15.05 | +12.31 |
CVS Health | CVS | Nov 4, 2024 | 54.65 | -2.08 |
CXApp A | CXAI | Nov 4, 2024 | 1.35 | -3.57 |
CyberArk Software | CYBR | Nov 4, 2024 | 274.10 | -0.75 |
Cybin | CYBN | Nov 4, 2024 | 10.12 | +1.30 |
Cyclacel Pharmaceuticals | CYCC | Nov 4, 2024 | 0.51 | -19.44 |
Cyclacel Pharmaceuticals Pref | CYCCP | Nov 4, 2024 | 7.50 | 0.00 |
Cyclerion Therapeutics | CYCN | Nov 4, 2024 | 2.64 | -10.63 |
Cyclo Therapeutics | CYTH | Nov 4, 2024 | 0.73 | +1.16 |
Cyngn | CYN | Nov 4, 2024 | 3.67 | +4.86 |
Cytek Biosciences | CTKB | Nov 4, 2024 | 5.20 | +1.76 |
Cytokinetics | CYTK | Nov 4, 2024 | 51.48 | -0.66 |
Cytomed Therapeutics | GDTC | Nov 4, 2024 | 2.48 | +7.73 |
CytomX Therapeutics | CTMX | Nov 4, 2024 | 1.01 | -3.81 |
Cytosorbents | CTSO | Nov 4, 2024 | 0.87 | -12.95 |
D-MARKET Electronic Services & Trading ADR | HEPS | Nov 4, 2024 | 3.23 | +0.94 |
D-Wave Quantum | QBTS | Nov 4, 2024 | 1.00 | -3.99 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.